Stifel Nicolaus analyst Adam Walsh reiterated a Buy rating on Ultragenyx (NASDAQ: RARE) yesterday and set a price target of $90. The company’s shares closed yesterday at $71.81.
According to TipRanks.com, Walsh is a 4-star analyst with an average return of 15.2% and a 48.5% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Galmed Pharmaceuticals, and Reata Pharmaceuticals.
Currently, the analyst consensus on Ultragenyx is a Strong Buy with an average price target of $83.44, which is a 16.2% upside from current levels. In a report issued on July 25, Cowen & Co. also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
Based on Ultragenyx’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $52.73 million. In comparison, last year the company had a GAAP net loss of $72.89 million.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
